Kyorin Pharmaceutical Co., Ltd.

Industry

  • Pharmaceuticals
    • Generic Drugs
    • Nutraceuticals
  • Biotechnology
    • Drug Discovery Technologies
      • Molecular Diversity
        • Natural Products

Other Names/Subsidiaries

  • ActivX Biosciences, Inc., KYORIN Holdings, Inc., Kyorin Rimedio
See more in Biomedtracker

Latest on Kyorin Pharmaceutical Co., Ltd.

Scrip

Asia Deal Watch: AstraZeneca Buys FibroGen’s Chinese Subsidiary

 
• By Joseph Haas, Vibha Ravi, Lisa Takagi, Dexter Jie Yan, and Jung Won Shin

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Deal Brings AstraZeneca Greater C

Scrip

Asia Deal Watch: Kaken Obtains Aadi Subsidiary And Cancer Drug Fyarro

 
• By Joseph Haas, Lisa Takagi, Ian Haydock, and Vibha Ravi

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Kaken Obtains Aadi’s Fyarro, Comm

Scrip

Asia Deal Watch: Ocumension Obtains Chinese Rights To Eight Alcon Products

 
• By Joseph Haas, Dexter Jie Yan, Vibha Ravi, and Anju Ghangurde

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. OcuMension Signs Stock-for-Rights

Scrip

Priothera Moves Mocravimod Into Pivotal Trials

 
• By Kevin Grogan

Priothera Limited , which has only been in operation for just over two years, can start thinking about regulatory submissions for its acute myeloid leukemia (AML) therapy mocravimod now that a late-st